Midatech Pharma PLC (LON:MTPH; NASDAQ:MTP) has hailed the positive results from a study assessing the potential to deliver one of its drugs via an injection under the skin rather than into the muscle.
MTD201, which is being developed to treat carcinoid cancer and the growth hormone condition acromegaly, was able to maintain the correct levels of plasma octreotide over six to eight weeks using this subcutaneous method, researchers found.
The extended timeframe provides MTD201 with an advantage over the current injections into the muscle, which last just four weeks.
Speaking about the results of Study 102, Midatech chief executive Craig Cook said: “It confirmed both the subcutaneous dosing route for MTD201, as well as the potential for extended dosing intervals.
“These are key advantages for patients, physicians and payors, being the first therapy to offer this, and also gives Midatech a competitive advantage versus others as we move the product through to potential approval."
The clinical assessment of the delivery mechanism for MTD201 confirmed the process was safe with a similar profile to the jab into the muscle tissue.
The ability to cut the injection burden to six from 12 a year would save time and money and allows the potential for self-administration, Midatech said.
MTD201 has already been shown to require a smaller gauge needle, which makes delivery less painful to administer, while the treatment itself is quick to make up too.
A ‘pivotal’ study if MTD201 is planned for later in the first half with preparations already underway.